Thaci, D.; Gordon , K. .; Gooderham, M.; Strober , B.; Korman, N.; Banerjee, S.; Banerjee, S.; Colston, E.; Kim, J.; Throup, J.; Morita, A. Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor, Compared With Placebo and Apremilast in Moderate to Severe Psoriasis: Integrated Laboratory Parameter Results From the Phase 3 POETYK PSO-1 and POETYK PSO-2 Trials. J of Skin 2021, 5, s37.